{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["55(6)"],"submitter":["Gokcay Canpolat A"],"pubmed_abstract":["<h4>Background/aim</h4>To describe Graves' Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control).<h4>Materials and methods</h4>Included in this multicenter matched case-control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID.<h4>Results</h4>The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TR"],"journal":["Turkish journal of medical sciences"],"pagination":["1381-1393"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12779019"],"repository":["biostudies-literature"],"pubmed_title":["Clinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study."],"pmcid":["PMC12779019"],"pubmed_authors":["Kara B","Balos Toruner F","Aydemir M","Cansu GB","Yalcin M","Polat SB","Alagol F","Omma T","Elhan AH","Yazici D","Alphan Uc Z","Gokcay Canpolat A","Bostan H","Oguz A","Batman A","Faki S","Asik M","Ucan B","Evren B","Ugur K","Kubat Uzum A","Mutlu U","Gurlek A","Ok AM","Sahin M","Ince N","Cesur M","Iliksu Gozu H","Yildiz BO","Karakilic E","Cakir B","Cakal E","Yilmaz M","Erdogan MF","Akcay S","Agbaht K","Erturk MS","Yorulmaz G","Saygili ES","Sah Unal T","Anil C","Unal MC","Ersoy R","Kayhan Y","Topaloglu O"],"additional_accession":[]},"is_claimable":false,"name":"Clinical characteristics of Graves' disease following COVID-19 infection or vaccination: a multicenter case-control study.","description":"<h4>Background/aim</h4>To describe Graves' Disease (GD) associated with COVID-19 infection (COVID) or its vaccines (VAC) and to compare the clinical presentations, laboratory parameters, and short-term clinical course of the disease among different etiology groups (COVID, VAC, and GD control).<h4>Materials and methods</h4>Included in this multicenter matched case-control, retrospective cohort study were 239 patients with newly diagnosed (n = 196) or recurrent GD (n = 43) associated with COVID (n = 79) or VAC (n = 160). Each case was matched (1:1) with a control who had been diagnosed with GD prior to COVID.<h4>Results</h4>The median age of the entire group was 42 years (female:male = 137:102). Both the COVID (4.6-fold) and VAC (4.1-fold) groups demonstrated higher TSH receptor antibody (TR","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-06T12:45:46.659Z","creation":"2026-05-30T03:11:38.411Z"},"accession":"S-EPMC12779019","cross_references":{"pubmed":["41509944"],"doi":["10.55730/1300-0144.6096"]}}